Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

MassBiologics gets FDA orphan drug designation for MBL-HCV1 antibody

CTCs serve as clinical tool to determine patient’s response to chemotherapy

CTCs serve as clinical tool to determine patient’s response to chemotherapy

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Researchers offer promise of strategy for curing HIV infection

Researchers offer promise of strategy for curing HIV infection

MiniVax wins $20,000 in NOBIC’s second annual BioChallenge business competition

MiniVax wins $20,000 in NOBIC’s second annual BioChallenge business competition

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra secures exclusive patent license for promising dengue virus antibodies from MIT

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.